Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)

Julie K. Bower, James S. Pankow, Mariana Lazo, Eric Christenson, Ron C. Hoogeveen, Christie M. Ballantyne, Marc K. Halushka, Brad C. Astor, Elizabeth Selvin

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Objectives: The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE. Design and methods: We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CVw) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants. Results: Mean sRAGE concentrations at the two time points (mean time between measurements=2.9years) were 1096.2pg/mL and 990.2pg/mL, respectively (mean difference=-106.0pg/mL, p-value<0.001). The Pearson's correlation was 0.78 (Spearman's, 0.73). The intra-class correlation coefficient was 0.76 and the CVw was 26.6%. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CVw for both was lower (8.7% for cholesterol, 15.6% for WBC). Less than 4% of participants' values changed substantially (50% or greater) over the three-year interval. Conclusions: We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.

Original languageEnglish (US)
Pages (from-to)132-134
Number of pages3
JournalClinical Biochemistry
Issue number1-2
StatePublished - Jan 2014

Bibliographical note

Funding Information:
This research was supported by NIH/NIDDK grant R01 DK076770 and a grant from the American Heart Association to Dr. Selvin, as well as NIH/NIDDK grant R01 DK056918 to Dr. Pankow. Dr. Bower was supported by NIH/NHLBI T32HL007024 Cardiovascular Epidemiology Training Grant. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts ( HHSN268201100005C , HHSN268201100006C , HHSN268201100007C , HHSN268201100008C , HHSN268201100009C , HHSN268201100010C , HHSN268201100011C , and HHSN268201100012C ). The authors thank the staff and participants of the ARIC study for their important contributions.


  • Advanced glycation end products
  • Biological markers
  • Reliability and validity


Dive into the research topics of 'Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)'. Together they form a unique fingerprint.

Cite this